Inmune Bio (INMB) Invested Capital (2017 - 2025)
Inmune Bio (INMB) has disclosed Invested Capital for 9 consecutive years, with $23.5 million as the latest value for Q4 2025.
- Quarterly Invested Capital fell 50.05% to $23.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Dec 2025, down 50.05% year-over-year, with the annual reading at $23.5 million for FY2025, 50.05% down from the prior year.
- Invested Capital hit $23.5 million in Q4 2025 for Inmune Bio, down from $25.4 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $90.6 million in Q1 2022 to a low of $23.5 million in Q4 2025.
- Historically, Invested Capital has averaged $53.2 million across 5 years, with a median of $50.6 million in 2023.
- Biggest five-year swings in Invested Capital: soared 183.66% in 2021 and later tumbled 50.05% in 2025.
- Year by year, Invested Capital stood at $80.2 million in 2021, then dropped by 18.85% to $65.1 million in 2022, then dropped by 27.29% to $47.3 million in 2023, then decreased by 0.51% to $47.1 million in 2024, then crashed by 50.05% to $23.5 million in 2025.
- Business Quant data shows Invested Capital for INMB at $23.5 million in Q4 2025, $25.4 million in Q3 2025, and $28.9 million in Q2 2025.